Biohaven

Biohaven FCF Growth

The Year-over-Year Free Cash Flow Growth of Biohaven (BHVN) as of Oct 27, 2026 is -4.03 %. In the previous year, Year-over-Year Free Cash Flow Growth was -75.19 % — a change of -94.64% (higher).

FCF Growth

-4.03 %

YoY

-94.64%

Last updated:

Year-over-Year Free Cash Flow Growth of Biohaven is 2025 -4.03 % . Year-over-Year Free Cash Flow Growth of Biohaven was 2024 -75.19 % . It decreases by -94.64% higher compared to the previous year.

The Biohaven FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-111.11 USD
Jan 1, 2019
-88.70 USD
Jan 1, 2020
79.29 USD
Jan 1, 2021
-86.61 USD
Jan 1, 2022
-130.80 USD
Jan 1, 2023
1.18 USD
Jan 1, 2024
-75.19 USD
Jan 1, 2025
-4.03 USD
The Biohaven FCF Growth history
YEARFCF GrowthYoY
-4.03 %-94.64%
-75.19 %-6,484.19%
1.18 %-100.90%
-130.80 %+51.02%
-86.61 %-209.23%
79.29 %-189.40%
-88.70 %-20.17%
-111.11 %-50.16%
-222.91 %-47.49%
-424.51 %+11.36%
-381.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Year-over-Year Free Cash Flow Growth of Biohaven is -4.03 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Biohaven since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biohaven

All Key Metrics — Biohaven